Genomic analysis of individual patients is now affordable and therapies targeted to specific molecular aberrations are being tested in clinical trials. However, even highly-specialized physicians at leading academic centers are not equipped to apply genomic information available in publically available sources to clinical- decision-making concerning individual patients. Our central hypothesis is that we can develop informatics tools to support personalized cancer treatment as """"""""standard of care"""""""" rather than """"""""one off"""""""" exceptions. We will: 1) implement a bioinformatics pipeline for processing molecular data into actionable profiles, 2) create and maintain a database of therapeutic implications of common genomic aberrations using automated processing of publically-available sources and 3) develop tools to summarize and present patient-specific advice to clinicians. These tools will be based on existing technologies and publicly available data sources. Once tested, we will make these tools available via appropriate open source license.
Genomic analysis of individual patients is now affordable and therapies targeted to specific molecular aberrations are being tested in clinical trials. In this project, we will develop informatics tools to support personalized cancer treatment as standard of care rather than one off exception.
|Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194|
|Sen, Shiraj; Hess, Kenneth; Hong, David S et al. (2018) Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer 118:763-769|
|Brusco, Lauren L; Wathoo, Chetna; Mills Shaw, Kenna R et al. (2018) Physician interpretation of genomic test results and treatment selection. Cancer 124:966-972|
|Kurnit, Katherine C; Dumbrava, Ecaterina E Ileana; Litzenburger, Beate et al. (2018) Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res 24:2719-2731|
|Meric-Bernstam, Funda; Zheng, Xiaofeng; Shariati, Maryam et al. (2018) Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol 2018:|
|Johnson, Amber; Khotskaya, Yekaterina B; Brusco, Lauren et al. (2017) Clinical Use of Precision Oncology Decision Support. JCO Precis Oncol 2017:|
|Arango, Natalia Paez; Brusco, Lauren; Mills Shaw, Kenna R et al. (2017) A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 8:41806-41814|
|Goldstein, Jennifer B; Tang, Chad; Hess, Kenneth R et al. (2017) Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget 8:87163-87173|
|Kurnit, Katherine C; Bailey, Ann M; Zeng, Jia et al. (2017) ""Personalized Cancer Therapy"": A Publicly Available Precision Oncology Resource. Cancer Res 77:e123-e126|
|Meric-Bernstam, F; Brusco, L; Daniels, M et al. (2016) Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 27:795-800|
Showing the most recent 10 out of 35 publications